329 related articles for article (PubMed ID: 29807823)
41. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
[TBL] [Abstract][Full Text] [Related]
42. Overactive bladder syndrome - management and treatment options.
Arnold J; McLeod N; Thani-Gasalam R; Rashid P
Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
[TBL] [Abstract][Full Text] [Related]
44. Overactive bladder - 18 years - Part II.
Truzzi JC; Gomes CM; Bezerra CA; Plata IM; Campos J; Garrido GL; Almeida FG; Averbeck MA; Fornari A; Salazar A; Dell'Oro A; Cintra C; Sacomani CA; Tapia JP; Brambila E; Longo EM; Rocha FT; Coutinho F; Favre G; Garcia JA; Castano J; Reyes M; Leyton RE; Ferreira RS; Duran S; Lopez V; Reges R
Int Braz J Urol; 2016; 42(2):199-214. PubMed ID: 27176185
[TBL] [Abstract][Full Text] [Related]
45. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
Leicht W; Hampel C; Thüroff J
Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
[TBL] [Abstract][Full Text] [Related]
46. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Con.
Siegel S
J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742452
[No Abstract] [Full Text] [Related]
47. [Therapy-refractory overactive bladder: alternative treatment approaches].
Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
[TBL] [Abstract][Full Text] [Related]
48. Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments.
Kirby AC; Park S; Cook SB; Odem-Davis K; Gore JL; Wolff EM
Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):431-436. PubMed ID: 32265405
[TBL] [Abstract][Full Text] [Related]
49. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.
Makovey I; Davis T; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2011 Nov; 30(8):1538-40. PubMed ID: 21826718
[TBL] [Abstract][Full Text] [Related]
50. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
51. [What to do if pills do not work for urge incontinence--still many questions and ambiguities].
Koldewijn EL
Ned Tijdschr Geneeskd; 2012; 156(33):A5099. PubMed ID: 22894810
[TBL] [Abstract][Full Text] [Related]
52. New evidence in the treatment of overactive bladder.
Brown ET; Martin L; Dmochowski RR
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
[TBL] [Abstract][Full Text] [Related]
53. The use of botulinum toxin a in idiopathic overactive bladder syndrome.
Gomez CS; Kanagarajah P; Gousse A
Curr Urol Rep; 2010 Sep; 11(5):353-9. PubMed ID: 20623260
[TBL] [Abstract][Full Text] [Related]
54. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Pro.
Ginsberg DA
J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742453
[No Abstract] [Full Text] [Related]
55. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review.
Booth J; Connelly L; Dickson S; Duncan F; Lawrence M
Neurourol Urodyn; 2018 Feb; 37(2):528-541. PubMed ID: 28731583
[TBL] [Abstract][Full Text] [Related]
56. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
Apostolidis A
Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
[TBL] [Abstract][Full Text] [Related]
57. Botulinum toxin in "refractory" detrusor overactivity. Re: Makovey I, et al. botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 2011;30:1538-1540.
Walsh CA; Moore KH
Neurourol Urodyn; 2012 Jun; 31(5):708. PubMed ID: 22488771
[No Abstract] [Full Text] [Related]
58. [Practical aspects of the use of botulinum toxin in the treatment of idiopathic overactive bladder].
Szczypior M; Matuszewski M
Wiad Lek; 2018; 71(4):888-892. PubMed ID: 30099430
[TBL] [Abstract][Full Text] [Related]
59. [Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome].
Deffieux X; Fatton B; Denys P; Chartier-Kastler E; Amarenco G; Haab F; Costa P; Game X; Karsenty G; Saussine C; Ballanger P; Le Normand L; Ruffion A; Hermieu JF; Cosson M
J Gynecol Obstet Biol Reprod (Paris); 2014 Oct; 43(8):572-80. PubMed ID: 25087018
[TBL] [Abstract][Full Text] [Related]
60. Where Are We Headed with Neuromodulation for Overactive Bladder?
Jaqua K; Powell CR
Curr Urol Rep; 2017 Aug; 18(8):59. PubMed ID: 28656519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
